Vasograin Tablet

Quick links to important sections

Vasograin Tablet

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vasograin Tablet

Property Description
Active Ingredients Ergotamine Tartrate, Caffeine Monohydrate, Paracetamol, Prochlorperazine Maleate
Form Oral Tablet
Pharmacological Class Antimigraine Preparations
General Purpose Acute, multi-modal relief from migraine symptoms
Type Fixed-dose combination product

Definition and Pharmacological Classification of Vasograin Tablet

Vasograin Tablet is a specific fixed-dose combination medication classified under the therapeutic category of Antimigraine Preparations, manufactured by Cadila Pharmaceuticals Ltd. (India). This drug is supplied as an oral tablet and utilizes a multi-modal pharmacological approach recognized for its ability to address the complex nature of severe headaches. Fixed-dose combinations are designed to simplify the necessary treatment regimen by integrating multiple active components into one system, a strategy recognized for its effectiveness in addressing symptoms requiring simultaneous physiological interventions, such as those present in an acute migraine attack.

Active Ingredients and Compositional Basis

The medication is defined by its four distinct active ingredients: Ergotamine Tartrate, Caffeine Monohydrate, Paracetamol (Acetaminophen), and Prochlorperazine Maleate. The inclusion of Prochlorperazine Maleate, a potent phenothiazine derivative, is notable for its established antiemetic properties, meaning it specifically targets and helps control the nausea and vomiting often associated with severe migraine attacks. Furthermore, the combination utilizes Ergotamine, a semi-synthetic ergot alkaloid derivative, whose primary action as a vasoconstrictor is complemented by the Central Nervous System (CNS) stimulant properties of Caffeine to enhance absorption and augment the vessel-constricting effect.

General Purpose of This Multi-Modal Relief

The general purpose of the Vasograin Tablet formulation is to provide immediate, comprehensive relief from the debilitating symptoms of an established migraine attack. The combination is engineered to work through synergistic physiological actions: inducing targeted vasoconstriction (to reduce vessel swelling), providing central pain signal modulation (to dull the pain sensation), and conferring an antinauseant effect (to block the signals that cause associated sickness). This structured approach ensures that the core throbbing pain, the abnormal vessel dilation, and the disruptive co-symptom of nausea are addressed concurrently in a single medication for a more complete therapeutic response.

What side effects are possible with Vasograin Tablet?

Possible Side Effects and Safety Information

The safety profile of Vasograin Tablet, a combination medication, is defined by the officially documented adverse effects associated with its active components, categorized by frequency and the body system affected, consistent with regulatory standards.

Commonly Documented Adverse Reactions

Adverse effects listed as common in regulatory documents typically involve Nervous System Disorders (such as drowsiness and dizziness) and Gastrointestinal Disorders (including nausea, vomiting, and dry mouth). Orthostatic hypotension and muscle pain are also reported as common occurrences.


Serious Adverse Reactions and Constraints

Regulatory documents emphasize the risk of Serious Adverse Reactions. These include Ergotism, a syndrome of severe and potentially life-threatening vasoconstriction; Neuroleptic Malignant Syndrome (NMS), a severe symptom complex associated with the phenothiazine component (Prochlorperazine); and the potential for severe Hepatotoxicity (liver damage) linked to Paracetamol, particularly with overuse. Rare reports of fibrotic changes (e.g., cardiac valvular fibrosis) are also documented with long-term continuous use of the ergotamine component. The medication is not suitable for chronic daily use and is restricted to the acute management of migraine attacks.


Population-Specific Safety Considerations

Use is Contraindicated in certain populations, including during Pregnancy due to the risk of fetal harm and in patients with severe Cardiovascular Disease (e.g., uncontrolled hypertension, coronary artery disease) or severe Hepatic or Renal Impairment. Safety and effectiveness have not been established in children and adolescents under 18. Concomitant use with other vasoconstrictors or strong CYP3A4 inhibitors is strictly Contraindicated due to the heightened risk of severe vasospasm.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Vasograin Tablet, which contains ergotamine, may lead to serious health consequences requiring prompt intervention. Taking an excessive amount can result in acute intoxication, or it may occur from chronic overuse. Prolonged use or exceeding the recommended dose carries a risk of the medicine becoming habit-forming, which can lead to medication overuse headache.

Overdose Presentation (Potential Symptoms) Systems Affected
Vomiting, numbness, tingling, pain Neurological/Gastrointestinal
Hypertension or hypotension, convulsions Cardiovascular/Neurological
Drowsiness, irregular heartbeats Neurological/Cardiovascular

Serious toxicity, often called ergotism, is associated with sustained vasoconstriction, a narrowing of the blood vessels. This effect can cause paleness, coldness, and loss of pulses in the hands and feet (paresthesias). In severe, prolonged cases, reduced blood flow may lead to tissue damage or gangrene.

Mandatory Emergency Actions

If you or someone else takes an excessive amount of Vasograin Tablet, seek medical attention immediately. Since a specific antidote is not widely available, treatment focuses on removing the drug from the body and providing supportive care to manage symptoms and prevent complications. Healthcare providers must be informed immediately about the amount taken.

Therapeutic Uses of Vasograin Tablet

What Vasograin Tablet Treats: Main Uses and Benefits

Vasograin Tablet is commonly used in the context of abortive therapy for established, acute migraine episodes. This combination is commonly used across conditions presenting with acute episodes where supportive symptom management is appropriate. It may assist with addressing symptom clusters that may become intense or disruptive, playing a role in managing the throbbing pain, nausea, and vomiting associated with a severe attack.


The formulation is applied during phases of increased distress, providing short-term symptomatic assistance. This is generally relevant when symptoms become temporarily overwhelming and may interfere with daily comfort. The dual-action approach supports the patient during these difficult episodes by easing distress from both the physical discomfort of the headache and the disruptive manifestations of gastric sickness.


Quick Fact: Relief for Migraine Symptoms

This medication is applied in addressing certain distressing symptoms, including pulsating pain, gastrointestinal distress, and related sensory hypersensitivity. This supportive relief may help patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview of Ergotamine and Caffeine

Eligibility and Restrictions for Use

Vasograin Tablet, which contains a combination of ergotamine, caffeine, paracetamol, and prochlorperazine, is generally used for the treatment of acute migraine attacks.

Who Can Use Vasograin Tablet?

This medication is intended for use in adults (typically 16 years of age and older) who have been specifically diagnosed with migraine and associated symptoms like nausea and vomiting. Its use should be limited to the treatment of an acute migraine and is not recommended for daily or preventive use.

Who Cannot Use Vasograin Tablet? (Contraindications)

Vasograin Tablet is contraindicated in individuals with a known allergy to any of its active components. It should not be used in:

  • Pregnancy and Breastfeeding: Due to potential risks to the fetus and nursing infant.
  • Cardiovascular Conditions: Including uncontrolled hypertension (high blood pressure), coronary heart disease, and peripheral vascular diseases, as the ergotamine component can narrow blood vessels.
  • Severe Organ Impairment: Patients with severe active liver or kidney disease.
  • Drug Interactions: If you are taking certain medications that inhibit the CYP3A4 enzyme, such as certain antibiotics (e.g., macrolides), antivirals, or antifungals, as this can dangerously increase ergotamine levels.
  • Other Migraine Medications: It should not be used concurrently with other ergot-containing medicines or triptans.

Patients with conditions like glaucoma, peptic ulcer, or a history of the neuroleptic malignant syndrome should use this medication with extreme caution and only under strict medical supervision.

What should I know about interactions with other medicines?

Interactions with other medicines and products for Vasograin Tablet

Interactions with Vasograin Tablet are primarily driven by the Ergotamine component and its metabolism via the CYP3A4 enzyme system, alongside pharmacodynamic risks.

Contraindicated Combinations

The most significant restriction involves the co-administration of agents that strongly inhibit the CYP3A4 enzyme. This metabolic inhibition dangerously increases the concentration of Ergotamine in the blood, leading to a severe risk of ergotism (prolonged and intense blood vessel narrowing).

  • Strong CYP3A4 Inhibitors: This includes specific Macrolide Antibiotics (e.g., Clarithromycin), certain Azole Antifungals (e.g., Itraconazole), and HIV Protease Inhibitors (e.g., Ritonavir).
  • Other Vasoconstrictors: The combination with all 5-HT1 receptor agonists (Triptans) is forbidden due to the high risk of additive and prolonged vasoconstriction. Other vasoconstrictive drugs or agents, including Nicotine, are also restricted.

Pharmacodynamic and Dietary Interactions

Other clinically significant interactions include a required 24-hour separation (washout period) when switching between Triptans and Vasograin. Caution is also advised when co-administering Beta-blockers, as they may potentiate Ergotamine's vascular effects. The concomitant use of Alcohol and consumption of Grapefruit juice should be avoided, as both are documented to affect the drug’s profile and increase the potential for adverse events.

Mechanism of Action

Vasograin Tablet is a combination pharmaceutical agent whose primary pharmacodynamic action involves receptor agonism and vasoconstriction. The Ergotamine component acts as a partial agonist at serotonin 5- HT1 B and 5- HT1 D receptors. Activation of these receptors on the vascular endothelium mediates the constriction of cranial blood vessels, specifically the extracranial arteries. Furthermore, 5- HT1 D receptor agonism affects the neural component by modulating the release of pro-inflammatory neuropeptides from perivascular trigeminal nerve endings, impacting neurogenic inflammation. The Caffeine component, which acts as an adenosine receptor antagonist and has intrinsic vasoconstrictive properties, functionally augments the vasoconstrictive effect elicited by Ergotamine, contributing to the overall system-level physiological modulation of cerebral vasculature.

Dosage and Administration Information

How to Use Vasograin Tablet: Administration Guidelines

This section details the administration instructions for the Vasograin Tablet fixed-dose combination.

Feature Instruction / Label Text
Route of administration Oral route only, administered as a tablet.
Dosing schedule (Adults) Initial Dose: 1 to 2 tablets taken at the first sign of the acute episode.
Subsequent Dosing 1 additional tablet may be taken every 30 minutes if relief is not achieved.
Maximum Limit Not to exceed 6 tablets per single acute episode, and 10 tablets within a 7-day period.
Timing in relation to meals May be administered with or without food.
Age-group rules Not recommended for patients under 18 years of age.

Resulting Procedural Structure

Step sequence:

  • Take the initial dose of 1 to 2 tablets orally at the first indication of an acute episode.
  • If needed, take 1 additional tablet 30 minutes after the initial dose, repeating as necessary.
  • Do not exceed the cumulative limit of 6 tablets for that acute episode.
  • Do not exceed the cumulative limit of 10 tablets within a period of 7 days.

Connection to the overall use protocol: The administration protocol establishes a time-sensitive procedure for the acute, intermittent use of the medication. This structure defines the oral route, the required initial and subsequent dose intervals, and the maximum quantities permitted per event and per week. The protocol restricts the drug’s application to as-needed episodes, prohibiting long-term or scheduled daily administration.

Recent Clinical Evidence

Research Evidence and Overview of Studies for Vasograin Tablet

This section outlines the types of clinical studies and research that form the basis for understanding the fixed-dose combination, focusing on study design, measured outcomes, and identified limitations. It provides context on what has been observed in research settings, but research does not determine whether an individual will respond similarly.


Evidence for Use in Acute Migraine Attacks

Vasograin Tablet is a fixed-dose combination, and the foundation of its use rests on research applied in studies examining short-term or episodic symptom patterns related to migraine. This combination was studied for its use in conditions characterized by fluctuating or episodic manifestations, specifically the acute phase of a migraine attack.

Research has explored various outcomes related to physical discomfort, primarily focusing on how changes in headache pain were measured during the study period. Studies monitored the proportion of patients who reported moving from a state of moderate or severe pain to a pain-free or pain-relieved state within specific, short time intervals, typically measured at defined time intervals, such as 2 hours. Short-term, controlled trials have been used in research examining temporary physiological imbalance associated with acute attacks.

The findings describe patterns observed in the studies related to pain status. Research highlights changes measured during the study period; however, the available evidence is largely based on the components rather than the exact four-drug combination. The data show patterns related to how symptoms evolved in the observed populations, and research provides insight into short-term changes in pain intensity.


Evidence for Associated Symptom Management

Research has explored the role of a component in the combination that was studied for its use in contexts involving nausea and vomiting, which are common symptoms observed during migraine. Studies monitored outcomes related to systemic or functional imbalance, such as the patient-reported experience of gastrointestinal distress.

Research describes how the component evaluated for outcomes related to nausea was evaluated in studies conducted during periods of increased symptom activity. Findings describe patterns observed in the studies regarding measured changes in the presence of nausea and vomiting at the time pain outcomes were measured. This evidence contributes to understanding symptom patterns and how patient-reported outcomes describing perceived discomfort were affected in the research scenarios.


What Remains Uncertain and Areas for Future Research

The structure of the available evidence varies across studies; data from many controlled trials often focus on the Ergotamine/Caffeine component rather than the full four-drug combination. The follow-up durations were limited, meaning that long-term effects are not fully established. Additionally, comparative evidence is lacking in contemporary research scenarios involving the full fixed-dose product versus newer treatments. Data show patterns related to how symptoms are measured, but the sample sizes were modest in some of the older trials supporting the components, and data are still emerging for a complete understanding of the fixed-dose combination across all patient groups and timeframes.

Key Studies & References Ergotamine and Caffeine (Oral Route) Drug Information

Frequently Asked Questions (FAQ)

Common questions about Vasograin Tablet (FAQ)


Q: How quickly does Vasograin Tablet start working?

A: Regulatory instructions advise taking the initial dose at the very first sign of a migraine attack. Official dosing guidelines permit taking a subsequent tablet after just 30 minutes if the initial dose has not provided relief. This short re-dosing interval in the label indicates that patients typically evaluate the medication's initial effectiveness within a relatively brief timeframe.


Q: Can Vasograin Tablet be taken with regular pain relievers like paracetamol or ibuprofen?

A: Vasograin Tablet already contains Paracetamol (Acetaminophen) as one of its active ingredients. The presence of paracetamol as an active ingredient should be noted. While official warnings focus on interactions with strong vasoconstrictors and certain antibiotics, standard non-steroidal pain relievers like Ibuprofen are not typically listed as being strictly prohibited in the product labeling.


Q: Is Vasograin Tablet safe for long-term use?

A: Regulatory documents indicate that this medication is not intended for chronic daily administration and is restricted to acute use. The prolonged, continuous use of the ergotamine component has been associated with rare, serious complications, such as fibrotic changes.


Q: What is the difference between Vasograin and a normal headache pill?

A: Vasograin is a fixed-dose combination of four active ingredients, which differs significantly from a single-ingredient analgesic. Its mechanism is multi-modal, meaning it works through several ways: by causing vasoconstriction (narrowing blood vessels), acting on pain signals, and providing an antinauseant effect to treat the common associated symptom of nausea.


Q: Why do some people experience nausea after taking Vasograin?

A: Although one component has antiemetic properties, nausea is still listed as a common adverse reaction in regulatory documents. This indicates that some patients may still experience this gastrointestinal side effect.


Q: Can I drink coffee or caffeine while on Vasograin?

A: This tablet already contains Caffeine Monohydrate as an active ingredient. The official label suggests caution regarding additional consumption of caffeine, such as from coffee, due to the potential for excessive stimulation or vascular effects.


Q: Can elderly people take Vasograin Tablet?

A: Regulatory information indicates that because patients over 65 may be more susceptible to vasoconstriction effects, use in this population requires careful consideration. This is due to the potential for effects on blood circulation.


Q: Is Vasograin Tablet used to prevent migraines or just treat them?

A: According to official indications, the medication is intended for the acute treatment of an established vascular headache episode. It is not approved or intended for the scheduled, daily prophylaxis (prevention) of chronic or recurrent migraines.


Q: Does Vasograin Tablet affect blood pressure?

A: Yes, Vasograin can affect blood pressure due to the vasoconstrictive (blood vessel narrowing) action of the ergotamine component. For this reason, official safety information contraindicates its use in patients with uncontrolled high blood pressure.


Q: What happens if you stop taking Vasograin suddenly?

A: The drug is only intended for intermittent, acute use. However, regulatory warnings address the risk of Medication Overuse Headache (MOH). If MOH is a factor, stopping the product may be associated with a temporary return or worsening of headaches.


Q: Are there any withdrawal symptoms from Vasograin?

A: The risk of Medication Overuse Headache (MOH) is linked to frequent use. In cases of MOH, cessation may be associated with a temporary worsening of headache symptoms, which should be monitored.


Q: How long does the effect of one Vasograin Tablet last?

A: The exact duration of the clinical effect is not published as a single time point, as it depends on the varying half-lives of the four components. The dosing regimen, which allows for re-dosing after 30 minutes, implies that the initial response to the medication is evaluated quickly.


Q: Can Vasograin be taken by teenagers for migraines?

A: Official dosing and safety information generally states that the safety and effectiveness of this combination have not been established in children and adolescents. Therefore, it is typically not recommended for patients under 18 years of age.


Q: Does Vasograin Tablet interact with alcohol?

A: Yes, regulatory documents clearly state that alcohol consumption is not recommended while taking this tablet. This combination may increase central nervous system side effects, such as drowsiness and dizziness, when combined with alcohol.


Q: What is the maximum number of Vasograin tablets you can take in a month?

A: Regulatory dosing limits provide a clear boundary, restricting patients to a maximum of 10 tablets within any 7-day period. The monthly limit is not explicitly stated in the label, but use should not exceed the established weekly maximum.


Q: Why do doctors prescribe Vasograin for cluster headaches sometimes?

A: The regulatory indication for the ergotamine component covers therapy to abort (stop) or prevent vascular headaches. Historically, this indication has included conditions such as histaminic cephalalgia (an older term for cluster headaches) in addition to migraine attacks.


Q: Can Vasograin Tablet cause rebound headaches?

A: Yes, official warnings highlight that Medication Overuse Headaches (often called rebound headaches) are a recognized and serious risk associated with the frequent or prolonged use of medications containing ergotamine.


Q: Why is it important to take Vasograin at the onset of a migraine?

A: The official administration instructions mandate that the initial dose must be taken at the first sign of an acute attack. This timing is specified in the regulatory instructions to help ensure the product is used early in the course of the headache, which is necessary for its intended action of aborting the vascular headache.


Q: Does Vasograin Tablet affect sleep patterns?

A: This medication can potentially affect sleep patterns due to its combination of ingredients. Adverse reaction lists include both drowsiness (linked to one component) and insomnia (linked to the Caffeine component) in certain patients.


Q: Is it normal to feel a tingling sensation after taking Vasograin?

A: A tingling sensation, known medically as paresthesias (often felt in the fingers and toes), is listed as a possible adverse reaction in regulatory documentation. This sensation is noted as a finding that should be discussed with a healthcare provider, as it may be related to vasoconstriction.


Q: Is Vasograin a prescription drug or can I buy it over-the-counter?

A: According to the official drug label, this medication requires a prescription. The label specifies: 'Caution: Federal Law Prohibits Dispensing Without Prescription'.


Q: Are there specific warnings for people with kidney or liver issues?

A: The medication is strictly contraindicated for use in patients with severe active liver or kidney disease. Use is also restricted in patients with severe active organ impairment, and careful consideration is needed for patients with less severe impairment.


Q: Does Vasograin Tablet contain caffeine?

A: Yes, Vasograin Tablet is a fixed-dose combination product that includes Caffeine Monohydrate as one of its four active ingredients.


Q: Are there any known drug-food interactions with Vasograin?

A: The official label notes that products such as Grapefruit and Grapefruit juice are restricted because they can interfere with the breakdown of ergotamine, which could lead to increased blood levels and a risk of severe vasoconstriction.


Q: What's the difference between Vasograin and similar ergot alkaloid medicines?

A: Vasograin Tablet stands out because it is a fixed-dose combination containing four active ingredients (Ergotamine, Caffeine, Paracetamol, and Prochlorperazine). Many other ergot alkaloid medicines contain fewer components, often just Ergotamine or Ergotamine plus Caffeine.


Q: Is it true that Vasograin can help with tension headaches too?

A: The regulatory indications clearly state that the product is intended for the treatment of migraine headaches or other vascular headaches. It is not approved or recommended for use in the treatment of simple tension headaches.


Q: How often do people need to take Vasograin for it to be effective?

A: The medication is intended for the intermittent, acute treatment of migraine episodes, not for chronic use. Effective use is achieved by adhering to the strict maximum dosing limits, which restrict use to no more than 6 tablets per attack and 10 tablets per 7-day period.


Q: Can Vasograin Tablet affect my driving ability?

A: Official patient counseling information includes warnings that this medication may cause side effects like drowsiness, dizziness, and numbness. These effects could potentially impair the mental or physical abilities required for tasks such as driving or operating machinery.


Q: What kind of research supports the effectiveness of Vasograin?

A: The efficacy is primarily supported by controlled clinical trials that studied the medication's use in patients with episodic migraine attacks. These studies measured key outcomes, such as the proportion of patients who achieved pain-free status within a defined short period after taking the medication.


Q: What are the benefits of using Vasograin compared to only using simple analgesics?

A: The key benefit, according to the official mechanism of action, is its multi-modal approach that provides vasoconstriction to target the underlying vascular issue in migraine. Additionally, it includes an antinauseant component that simple pain relievers do not offer, addressing a major associated symptom.

How should Vasograin Tablet be stored and disposed of?

The official labeling provides mandatory conditions for the storage and disposal of Vasograin Tablet to ensure product stability and safety.

Storage Requirement Condition
Temperature Store below 30 C.
Protection Store in a cool, dry place, protected from light and moisture.
Packaging Keep in the original container/packet and ensure it is tightly closed.
Safety Keep out of the sight and reach of children and pets at all times.

Disposal of unused or expired tablets must follow regulatory guidelines. The medicine is not on the FDA's flush list and must not be flushed down the toilet. If a drug take-back program is unavailable, dispose of in the household trash by mixing the tablets with an undesirable substance, sealing the mixture in a container, and discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vasograin Tablet found in:

A-Z Index: